



Universiteit  
Leiden  
The Netherlands

## Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics

Lunenburg, C.A.T.C.

### Citation

Lunenburg, C. A. T. C. (2019, June 11). *Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics*. Retrieved from <https://hdl.handle.net/1887/74404>

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/74404>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The following handle holds various files of this Leiden University dissertation:


<http://hdl.handle.net/1887/74404>

**Author:** Lunenburg, C.A.T.C.

**Title:** Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics

**Date:** 2019-06-11

# **PERSONALISED MEDICINE OF FLUOROPYRIMIDINES USING *DPYD* PHARMACOGENETICS**



**Carin Lunenburg**

The research presented in this thesis was performed at the department of Medical Oncology and the department of Clinical Pharmacy and Toxicology of Leiden University Medical Center, Leiden, The Netherlands. Financial support for publication of this thesis was provided by departmental funds from the departments of Medical Oncology and Clinical Pharmacy & Toxicology of the Leiden University Medical Center, Leiden, the Netherlands.

The research described in this thesis has been made possible by funding from the Dutch Cancer Society (Alpe-d'HuZes/KWF-fund NKI2013-6249) and the Dutch foundation ZonMw (Goed Gebruik Geneesmiddelen/ project number 848016007). Carin Lunenburg was supported by an unrestricted grant from Roche Pharmaceuticals. There was no involvement in the study design, data collection, analysis or interpretation of the data.

Cover design: Carin Lunenburg  
Lay out: Loes Kema  
Printed by: GVO drukkers en vormgevers B.V.  
ISBN: 978-94-6332-500-4

© C.A.T.C. Lunenburg 2019

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage or retrieval, without permission in writing from the author.

# **Personalised medicine of fluoropyrimidines using *DPYD* pharmacogenetics**

**Proefschrift**

ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,  
volgens besluit van het College voor Promoties  
te verdedigen op dinsdag 11 juni 2019  
klokke 15.00 uur

door

**Carin Adriana Theodora Catharina Lunenburg**

geboren te Oss  
in 1990

|                         |  |
|-------------------------|--|
| Promotores              | Prof. dr. A.J. Gelderblom<br>Prof. dr. H.-J. Guchelaar   |
| Copromotor              | Dr. J.J. Swen  |
| Leden promotiecommissie | Prof. dr. J.H. Beijnen<br>University of Utrecht, Netherlands Cancer Institute Amsterdam<br>Prof. dr. C.M. Cobbaert<br>Prof. dr. J.A. Gietema<br>University of Groningen, University Medical Center Groningen |

You can never cross the ocean  
unless you have the courage to lose sight of the shore

-  
*Christopher Columbus*  
1451-1506

## Contents

|           |                      |   |
|-----------|----------------------|---|
| Chapter 1 | General introduction | 9 |
|-----------|----------------------|---|

### ***DPYD* genotyping: proof of principle and implementation in clinical practice**

---

|           |  |     |
|-----------|--|-----|
| Chapter 2 | Prospective <i>DPYD</i> genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time<br><i>Eur J Cancer. 2016;54:40-8</i>                             | 23  |
| Chapter 3 | Translating <i>DPYD</i> genotype into DPD phenotype: using the <i>DPYD</i> gene activity score<br><i>Pharmacogenomics. 2015;16(11):1277-86</i>   | 39  |
| Chapter 4 | Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of <i>DPYD</i> and fluoropyrimidines<br><i>Submitted (under review)</i>                              | 57  |
| Chapter 5 | <i>DPYD</i> genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis<br><i>Lancet Oncol. 2018;19(11):1459-1467</i>      | 149 |
| Chapter 6 | A cost analysis of upfront <i>DPYD</i> genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy<br><i>Eur J Cancer. 2018;107:60-7</i>                         | 179 |
| Chapter 7 | Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in <i>DPYD</i> variant allele carriers<br><i>Eur J Cancer. 2018;104:210-8</i> | 193 |
| Chapter 8 | Evaluation of clinical implementation of prospective <i>DPYD</i> genotyping in 5-fluorouracil- or capecitabine-treated patients<br><i>Pharmacogenomics. 2016;17(7):721-9</i>             | 215 |
| Chapter 9 | Confirmation practice in pharmacogenetic testing; how good is good enough?<br><i>Clin Chim Acta. 2018;490:77-80</i>  | 231 |



## **Beyond current *DPYD* pharmacogenetics**

---

|            |  |     |
|------------|--|-----|
| Chapter 10 | Comparison of four phenotyping assays for predicting dihydropyrimidine dehydrogenase (DPD) deficiency and severe fluoropyrimidine-induced toxicity: a clinical study<br><i>Manuscript in preparation</i> | 253 |
| Chapter 11 | Diagnostic and therapeutic strategy for fluoropyrimidine treatment of patients carrying multiple <i>DPYD</i> variants<br><i>Genes 2018;9(12):585</i>   | 279 |
| Chapter 12 | Genome-wide association study to discover novel genetic variants related to the onset of severe toxicity following fluoropyrimidine use<br><i>Manuscript in preparation</i>                              | 303 |

## **General discussion, summaries and appendix**

---

|            |  |     |
|------------|--|-----|
| Chapter 13 | General discussion and future perspectives | 321 |
| Chapter 14 | Summary                                    | 341 |
|            | Nederlandse samenvatting                   | 345 |
| Appendix   | List of publications                       | 354 |
|            | Courses and training activities            | 357 |
|            | Curriculum vitae                           | 359 |
|            | Dankwoord                                  | 360 |